Zai Lab Advances DLLEVATE Trial In Relapsed Small Cell Lung Cancer

Zai Lab Ltd (ZLAB) announced an update on their ongoing clinical study.

Zai Lab Ltd. is advancing a late stage study called DLLEVATE that compares its drug ZL-1310 with standard options in people whose small cell lung cancer has come back. The goal is to see if ZL-1310 can improve outcomes versus current care, which could support a new treatment route in a cancer area with few good options.

The study tests ZL-1310, a targeted cancer drug that links an antibody to a cell killing agent, against doctor’s choice of existing drugs. Those options include topotecan, lurbinectedin, or amrubicin, which are used today but have limited impact for many patients.

The trial is an interventional study where patients are randomly assigned to either ZL-1310 or one of the standard therapies. It is open label, so both doctors and patients know which drug is given, and the main aim is to test how well the new drug works as a treatment.

The study was first submitted in October 2025, marking the start of formal trial setup and enrollment. The record was last updated on March 11, 2026, which signals recent activity and progress but final completion and main results are still ahead.

For investors, the update points to steady execution of a key Phase 3 asset that could become a growth driver if results are positive. Success could lift sentiment around Zai Lab’s pipeline and pressure rivals in small cell lung cancer, while setbacks would likely weigh on the stock given high expectations for late stage oncology assets.

The DLLEVATE study of ZL-1310 in relapsed small cell lung cancer remains active and updated, with further details available on the ClinicalTrials portal.

To learn more about ZLAB’s potential, visit the Zai Lab Ltd drug pipeline page.